Professor David Thomas

Prof Thomas is Head of the Cancer Division at the Garvan Institute of Medical Research, and Director of The Kinghorn Cancer Centre.  He is a NHMRC Principal Research Fellow and medical oncologist whose focus is on the application of genomic technologies to the understanding and management of cancer.  Prof Thomas founded the Australasian Sarcoma Study Group, a national research organisation, and established Australia’s leading adolescent and young adult cancer unit at the Peter MacCallum Cancer Centre.  Dr Thomas leads the International Sarcoma Kindred Study, now recruiting from 23 centres in 7 countries, and led the first international study of denosumab in Giant Cell Tumor of bone, leading to FDA and TGA approval.  He has over 150 research publications, including lead or senior author papers in Cancer Cell, Molecular Cell, Journal of Clinical Investigation, Lancet Oncology, JAMA Oncology, and Journal of Clinical Oncology. Since moving to NSW, he has established the Genomic Cancer Medicine Program, a multi-institutional precision medicine program for patients with rare and early onset cancers.  He is a member of Sydney Catalyst's Governing Council & Scientific Advisory Committees and in 2018, he became President of the Connective Tissue Oncology Society, the peak international body in his field.